Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

CRISPR gene editing proves safe in a clinical trial

Immune cells whose genomes have been altered with CRISPR are well-tolerated by three people with cancer.
CRISPR-CAS9 gene editing complex.

The CRISPR–Cas9 enzyme complex (blue and grey) edits DNA (purple). Participants in one of the earliest clinical trials of a CRISPR-based therapy experienced no serious side effects. Credit: Ella Maru Studio/Science Photo Library

Preliminary results from one of the earliest clinical trials of CRISPR—Cas9 provide evidence that the technique is safe and feasible to use for treating human diseases.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 578, 195 (2020)

doi: https://doi.org/10.1038/d41586-020-00339-3

References

Subjects

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links